Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent form (ICF) must be given~* Laboratory diagnosis of respiratory syncytial virus (RSV) infection~* The participant has an acute respiratory illness~* The time of onset of RSV symptoms to the anticipated time of randomization must be less than or equal to (\<=) 5 days~* Except for the RSV-related illness, the Participant must be medically stable in case of allowed co-morbid conditions~* The participant must have been assessed per local public health practice and considered not to have Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this respiratory infection~Exclusion Criteria:~* The participant is less than (\<) 3 months postnatal age at screening and was born prematurely (i.e, \<37 weeks and 0 days of gestation) OR if the participant weighs \<2.4 kilogram (kg) or greater than (\>) 16.8 kg~* Participant is considered by the investigator to be immunocompromised within the past 12 months~* Participant unwilling or unable to undergo mid-turbinate nasal swab procedures~* Participant is receiving chronic home oxygen therapy at screening~* Participant has other clinically significant abnormal electrocardiogram (ECG) findings not consistent with the present risk factor for severe RSV disease (if applicable) in the study population, as judged by the investigator based on the machine read ECG results at screening~* The participant has a QTcF interval greater than (\>)450 millisecond (ms) per the machine read (mean of triplicate) parameter result confirmed by repeat triplicate ECG recording during screening

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- High Dose: JNJ-53718678 (Type: EXPERIMENTAL): Participants will be randomized to receive JNJ-53718678 2.5 milligram per kilogram (mg/kg) (Age Group 1: greater than or equal to \[\>=\] 28 days and less than \[\<\] 3 months of age), 3 mg/kg (Age Group 2: \>=3 months and \<6 months of age) and 4.5 mg/kg (Age Group 3: \>=6 months and less than or equal to \[\<=3\] years of age) orally twice daily for 7 days.
- Low Dose: JNJ-53718678 (Type: EXPERIMENTAL): Participants will be randomized to receive JNJ-53718678 0.85 mg/kg (Age Group 1: \>=28 days and \<3 months of age), 1 mg/kg (Age Group 2: \>=3 months and \<6 months of age) and 1.5 mg/kg (Age Group 3: \>=6 months and 3 years of age) orally twice daily for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be randomized to receive matching placebo (i.e. high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose) orally twice daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy